Trulieve Gains Preliminary Entry Into the Russell 3000 Index
LONDON – Trulieve Cannabis Corp. has been preliminarily selected to join the Russell 3000 Index, placing one of the largest medical Cannabis operators in the United States on the cusp of entering a benchmark tracked by trillions of dollars in passive institutional capital.
The Russell 3000 Index measures the performance of the 3,000 largest publicly traded American companies and represents roughly 98% of the investable domestic equity market. Based on a market capitalization of approximately $1.86 billion, Trulieve falls below the $5.8 billion cutoff separating large cap and small cap constituents, positioning the stock within the small cap Russell 2000 segment.
FTSE Russell returned its domestic indexes to a semiannual rebalance schedule in 2026, making this the first December reconstitution in more than three decades. Under the official December reconstitution calendar, the preliminary roster undergoes a query period from November 16 through November 27 before a lockdown phase starts on November 30. Final additions take effect after the close of trading on December 11, with reconstituted index trading beginning on December 14.
Trulieve became eligible for broad domestic benchmarks through a sequence of regulatory and corporate adjustments completed this year:
- Following the federal order in April that placed state licensed medical Cannabis under Schedule III of the Controlled Substances Act, the company separated and deconsolidated its mixed medical and adult-use Harvest operations in early June.
- Days later, Trulieve began trading on the New York Stock Exchange, becoming the first plant touching American Cannabis operator on a major domestic exchange.
- In August, the company relocated its corporate domicile from British Columbia to Delaware, satisfying domestic incorporation requirements for American index providers.
- By September, Trulieve had secured entry into the S&P Total Market Index and S&P Completion Index.
The index milestone arrives shortly after Trulieve released its Q3 2026 financial results, reporting $230 million in revenue, a 64% gross margin, and $327 million in cash reserves. Management also confirmed that its medical facilities had received final DEA registrations aligned with the Schedule III framework. Another state licensed operator, Glass House Brands, also appeared on the December preliminary additions roster, underscoring broader benchmark eligibility across compliant operators.
Inclusion in the Russell family carries practical implications beyond symbolic recognition. Roughly $12.5 trillion in assets are benchmarked to Russell domestic indexes, meaning mutual funds and exchange traded funds that replicate those portfolios must purchase shares upon final confirmation.
Historically, state legal Cannabis companies relied heavily on retail traders and specialized sector funds, leaving shares vulnerable to wide liquidity swings and elevated borrowing costs. Entering core institutional benchmarks introduces steady, rules based demand and broader analyst scrutiny. At the same time, index membership subjects Trulieve to wider market correlations and requires sustained compliance with federal medical regulations, tying future capital access directly to operational discipline and regulatory execution.






































